摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 2-thiophen-2-yl-benzoxazole-6-carboxylate | 1346701-28-7

中文名称
——
中文别名
——
英文名称
methyl 2-thiophen-2-yl-benzoxazole-6-carboxylate
英文别名
methyl 2-thiophen-2-yl-1,3-benzoxazole-6-carboxylate
methyl 2-thiophen-2-yl-benzoxazole-6-carboxylate化学式
CAS
1346701-28-7
化学式
C13H9NO3S
mdl
——
分子量
259.285
InChiKey
POXRHLLCEIIQDF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    80.6
  • 氢给体数:
    0
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    methyl 2-thiophen-2-yl-benzoxazole-6-carboxylate 在 chromium dichloride 、 nickel dichloride manganese(IV) oxide 、 lithium aluminium tetrahydride 作用下, 以 四氢呋喃二氯甲烷二甲基亚砜 为溶剂, 反应 0.5h, 生成 ethyl (E)-4-hydroxy-4-(2-thiophen-2-yl-benzoxazol-6-yl)-but-2-enoate
    参考文献:
    名称:
    [EN] PYRIDAZINONES AS GPR119 AGONISTS
    [FR] PYRIDAZINONES UTILISÉS COMME AGONISTES DU RÉCEPTEUR GPR-119
    摘要:
    公开号:
    WO2011138427A3
  • 作为产物:
    描述:
    4-氨基-3-羟基苯甲酸硫酸 作用下, 以 乙醇 为溶剂, 反应 13.0h, 生成 methyl 2-thiophen-2-yl-benzoxazole-6-carboxylate
    参考文献:
    名称:
    Structure-based inhibition of acetylcholinesterase and butyrylcholinesterase with 2-Aryl-6-carboxamide benzoxazole derivatives: synthesis, enzymatic assay, and in silico studies
    摘要:
    An important research topic is the discovery of multifunctional compounds targeting different disease-causing components. This research aimed to design and synthesize a series of 2-aryl-6-carboxamide benzoxazole derivatives that inhibit cholinesterases on both the peripheral anionic and catalytic anionic sides. Compounds (748) were prepared from 4-amino-3-hydroxybenzoic acid in three steps. The Ellman test, molecular docking with Maestro, and molecular dynamics simulation studies with Desmond were done (Schrodinger, 12.8.117). Compound 36, the most potent compound among the 42 new compounds synthesized, had an inhibitory concentration of IC50 12.62 nM for AChE and IC50 25.45 nM for BChE (whereas donepezil was 69.3 nM and 63.0 nM, respectively). Additionally, compound 36 had docking values ​​of − 7.29 kcal/mol for AChE and − 6.71 kcal/mol for BChE (whereas donepezil was − 6.49 kcal/mol and − 5.057 kcal/mol, respectively). Furthermore, molecular dynamics simulations revealed that compound 36 is stable in the active gorges of both AChE (average RMSD: 1.98 Å) and BChE (average RMSD: 2.2 Å) (donepezil had average RMSD: 1.65 Å and 2.7 Å, respectively). The results show that compound 36 is a potent, selective, mixed-type dual inhibitor of both acetylcholinesterase and butyrylcholinesterase. It does this by binding to both the catalytically active and peripheral anionic sites of cholinesterases at the same time. These findings show that target compounds may be useful for establishing the structural basis for new anti-Alzheimer agents. Graphical abstract
    DOI:
    10.1007/s11030-024-10828-6
点击查看最新优质反应信息

文献信息

  • Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists
    申请人:Grauert Matthias
    公开号:US08772323B2
    公开(公告)日:2014-07-08
    The present invention relates to pyridazinone derivatives of general formula I, wherein the groups A, G and R1 are as defined in the application, the tautomers thereof, stereoisomers thereof, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
    本发明涉及一般式I的吡啶咪唑酮衍生物,其中A、G和R1基团如申请中所定义,其互变异构体、立体异构体、混合物和盐具有有价值的药理特性,特别是与GPR119受体结合并调节其活性。
  • PYRIDAZINONES AS GPR119 AGONISTS
    申请人:Grauert Matthias
    公开号:US20130172323A1
    公开(公告)日:2013-07-04
    The present invention relates to pyridazinone derivatives of general formula I, wherein the groups A, G and R 1 are as defined in the application, the tautomers thereof, stereoisomers thereof, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
    本发明涉及一般式I的吡啶咪唑酮衍生物,其中A、G和R1基团如本申请中所定义,其互变异构体、立体异构体、其混合物和其盐,具有有价值的药理特性,特别是能够结合GPR119受体并调节其活性。
  • US8772323B2
    申请人:——
    公开号:US8772323B2
    公开(公告)日:2014-07-08
查看更多

同类化合物

(N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) 钙离子载体A23187半镁盐 钙离子载体A23187半钙盐 萘并[2,3-d]噁唑-2,8(3H,5H)-二酮,6,7-二氢-5-甲基- 萘并[2,3-d]噁唑-2,5-二酮,3,6,7,8-四氢-3,8-二甲基- 荧光增白剂EBF 苯并恶唑胺 苯并恶唑的取代物 苯并恶唑甲磺酰氯 苯并恶唑基-2-甲酰基-S-乙基-异缩氨基硫脲 苯并恶唑-2-羧酸酰肼 苯并恶唑-2-磺酸 苯并恶唑-2-甲酸 苯并恶唑-2-甲磺酸钠 苯并恶唑-2-乙酸 苯并恶唑 苯并噁唑-5-甲酸 苯并噁唑-2-羧酸乙酯 苯并噁唑-2-甲醛 苯并噁唑,5,7-二(1,1-二甲基乙基)-2-乙烯基- 苯并噁唑,5,7-二(1,1-二甲基乙基)-2-乙基- 苯并噁唑,4,7-二氯-2-(氯甲基)- 苯并噁唑,2-叠氮- 苯并噁唑,2-(氯甲基)-4,7-二氟- 苯并[d]恶唑-7-甲酸甲酯 苯并[d]恶唑-5-硼酸频哪醇酯 苯并[d]噁唑-6-甲醛 苯并[d]噁唑-2-羧酸甲酯 苯并[d]噁唑-2-甲醇 苯并[D]恶唑-7-胺 苯并[D]噁唑-4-基氨基甲酸叔丁酯 苯并[D]噁唑-2-羧酸钾 苯并-13C6-噁唑 离子载体 碘化二氢2-[3-(5,6-二氯-1,3-二乙基-1,3--2H-苯并咪唑-2-亚基)丙-1-烯基]-3-乙基-5-苯基苯并噁唑正离子 硫代偏糖醛 甲酰胺,N-乙基-N-[6-[(3-甲酰基苯氧基)甲基]-2-苯并噁唑基]- 甲酰胺,N-[6-(溴甲基)-2-苯并噁唑基]-N-乙基- 甲基硫酸1-甲基-8-[(甲基氨基甲酰)氧代]喹啉正离子 甲基6-氨基-1,3-苯并恶唑-2-羧酸酯 甲基2-氨基-1,3-苯并恶唑-5-羧酸酯 甲基1,3-苯并恶唑-2-基乙酸酯 甲基-2-乙基-1,3-苯并唑-5-羧酸乙酯 甲基-1,3-苯并唑-5-羧酸乙酯 环戊二烯并[e][1,3]恶嗪-5,6-二胺 环戊二烯并[d][1,3]恶嗪-6,7-二胺 溴氯唑酮 溴化二氢2-[3-[1-[4-[(乙酰氨基)磺基基]丁基]-5,6-二氯-3-乙基-1,3--2H-苯并咪唑-2-亚基]丙-1-烯基]-3-乙基-5-苯基苯并噁唑正离子 氰基二硫代亚氨酸(6-氯-2-氧代-3(2H)-苯并恶唑基)甲基甲基酯 氰基-二硫代亚氨酸甲基(2-氧代-3(2H)-苯并恶唑基)甲基酯